ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 044

Validation of Newly Proposed Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis: A Virginia Cohort

Kelley Lee1, Ashley Kim2 and Aarat Patel3, 1University of Richmond, Richmond, VA, 2University of Virginia, Charlottesville, VA, 3Bon Secours Mercy Health / University of Virginia, GLEN ALLEN, VA

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: Autoinflammatory diseases, classification criteria, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Thursday, March 30, 2023

Title: Posters: Clinical and Therapeutic I

Session Type: Poster Session A

Session Time: 6:00PM-7:00PM

Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an aseptic autoinflammatory bone disease of unknown etiology. This diagnosis can be delayed due to the non-specific nature of symptoms, referral patterns to non-rheumatology specialists and normal imaging studies. New classification criteria have been proposed for CNO and were presented at the American College of Rheumatology scientific meeting in 2022. This study seeks to validate these new classification criteria.

Methods: This is a retrospective case-series of pediatric patients diagnosed with CNO (n=34). They were diagnosed and managed between 2012 and 2022 at the University of Virginia in Charlottesville, Virginia and Bon Secours Mercy Health in Richmond, Virginia. The entry criteria of chronic bone pain, age 18 years, abnormal radiograph and/or MRI were used prior to applying the newly proposed classification criteria. Tendomains were evaluated to indicate whether a patient has CNO; those who scored 55 points or higher qualified (see table). The clinical manifestations, laboratory results, and imaging studies that lead to a diagnosis of CNO were reviewed in detail. We applied and validated the newly proposed classification criteria for CNO to this Virginia cohort of previously diagnosed pediatric CNO patients. We also reviewed the characteristics of those that did not fulfill this classification criteria.

Results: Upon application of the newly proposed classification criteria for CNO, 31 out of 34 patients (91%) were found to meet this classification criteria. Of those that did not fulfill the criteria but carry the diagnosis of CNO (n=3) none had “least specific sites” such as hands orneurocranium, all had elevated ESR and two out of three had an initial response to antibiotics. Their scores were 49, 51 and 53 with classification criteria being met with 55 or higher. The average age of diagnosis was 10 (range 2-17) years-old with the average time between onset of symptoms to confirmed radiographic evidence being 25 (range 1-120) months. The most common presenting symptoms were bone pain (100 %) and arthritis (52%) with fever (23%) and rash (3%) being less common. Elevated ESR (39%) and CRP (39%) were found at initial visit with rheumatology. Evidence of commonly seen radiographic abnormalities leading to CNO diagnosis was found with regional MRI (65%), bone scan (42%) with some requiring full body MRI (26%) to confirm other lesions. Some patients did have multiple imaging studies including X-ray, CT, bone scan, MRI and bone biopsy in their workup.

Conclusion: This retrospective chart review validates the newly proposed classification criteria for CNO. We conclude that these criteria are easy to apply even in the absence of a bone biopsy or advanced imaging studies. This will aid in the development of a homogeneous cohort for future studies in CNO.

Supporting image 1


Disclosures: K. Lee: None; A. Kim: None; A. Patel: AbbVie/Abbott, 1, 6, Amgen, 6, Eli Lilly, 6, GlaxoSmithKlein(GSK), 6.

To cite this abstract in AMA style:

Lee K, Kim A, Patel A. Validation of Newly Proposed Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis: A Virginia Cohort [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/validation-of-newly-proposed-classification-criteria-for-pediatric-chronic-nonbacterial-osteomyelitis-a-virginia-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-newly-proposed-classification-criteria-for-pediatric-chronic-nonbacterial-osteomyelitis-a-virginia-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology